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Abstract
Background: We recently published the rare detection of xenotropic murine leukemia virus-related virus (XMRV) (1/105) in
prostate cancer (PCA) tissue of patients in Northern Europe by PCR. The controversial discussion about the virus being
detected in PCA tissue, blood samples from patients suffering from chronic fatigue syndrome (CFS), as well as from a
significant number of healthy controls prompted us to deepen our studies about detection of XMRV infection applying
different detection methods (PCR, cocultivation and immunohistochemistry [IHC]).
Methodology/Principal Findings: Peripheral blood mononuclear cells (PBMCs) from 92 PCA and 7 healthy controls were isolated,
PHA activated and cocultivated with LNCaP cells for up to 8 weeks. Supernatant of these cells was applied to a reporter cell line,
DERSE-iGFP. Furthermore, the PBMCs and cocultivated LNCaP cells were tested for the presence of XMRV by PCR as well as Western
Blot analysis. While all PCR amplifications and Western Blot analyses were negative for signs of XMRV infection, DERSE-iGFP cells
displayed isolated GFP positive cells in three cases. In all three cases XMRV presence could not be confirmed by PCR technology. In
addition, we performed XMRV specific IHC on PCA tissue sections. Whole tissue sections (n=20), as well as tissue microarrays (TMA)
including 50 benign prostate hyperplasia (BPH), 50 low grade and 50 high grade PCA sections and TMAs including breast cancer,
colon cancer and normal tissues were stained with two XMRV specific antisera. XMRV protein expression was not detected in any
cancer sections included. One BPH tissue displayed XMRV specific protein expression in random isolated basal cells.
Conclusion: We were unable to conclusively detect XMRV in the blood from PCA patients or from healthy controls and there is no
conclusive evidence of XMRV protein expression in PCA, breast cancer and colon cancer tissue sections tested by IHC staining.
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Introduction
Currently, the detection of Xenotropic Murine Leukaemia Virus
related Retrovirus (XMRV) in human bio specimens is controver-
sially discussed ranging from XMRV being associated with two
major human diseases, chronic fatigue syndrome (CFS) [1,2] and
prostate cancer (PCA) [3,4] to being a men generated laboratory
contaminant due to xenograft passaging through mice [5–18].
In 2006, XMRV has been identified in prostate tissue from
patients with familiar prostate cancer (PCA) carrying a homozy-
gous mutation within the RNaseL gene (R462Q) [19]. The
association between XMRV and PCA was severely strengthened
by studies demonstrating XMRV protein expression as well as the
presence of XMRV sequences in up to 26% of all PCA cases
[3,4,20]. XMRV protein expression was predominantly seen in
malignant epithelium suggesting a more direct role in tumorigen-
esis. However, there are multiple studies only rarely or completely
failing to detect XMRV in prostate cancer samples using PCR or
IHC methods [3,4,9,21–26]. We recently detected XMRV at low
frequency (1%) in sporadic PCA samples from Northern Europe
using PCR amplification methods and RNA isolated from fresh
frozen tissue specimens [27]. Expression of XMRV protein as well
as the presence of XMRV sequences in up to 26% of all analysed
PCA samples was demonstrated in 2009 by applying immunohis-
tochemistry (IHC) of whole mount PCA sections with an anti-
XMRV specific antiserum [4,20]. However, a recent report using
Rauscher MLV gag antisera which also recognizes XMRV gag
protein, did not confirm these findings [24]. The study by
Schlaberg et al. prompted us to revisit the prevalence of XMRV in
PCA samples by IHC since focal infections seen by IHC might be
missed in PCR analysis. In addition, we evaluate the presence of
XMRV protein expression in sections of other malignancies as
well as normal tissue by IHC. By using the recently published anti-
XMRV antiserum [4] as well as an XMRV gag specific antiserum
we were unable to detect XMRV gag specific staining of cells in
PCA or other cancerous tissue. However, one benign prostate
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25592hyperplasia (BPH) section clearly displayed positive stained cells
using anti-XMRV gag k121 serum.
In 2009 XMRV was identified in up to 68% of PBMC
(peripheral blood mononuclear cells) samples from patients with
chronic fatigue syndrome and 3–4% of the control cohort showed
signs of XMRV infection [2]. PCR data were strengthened by cell
dependent as well as cell free transmission of the virus from blood
samples of CFS patients to indicator cells. However, several
subsequent studies by other labs failed to confirm the PCR data
and no virus transmission experiments have been reproduced to
date [6,9,10,11,13,15,17,18,28,29,30,31]. Recently, blood samples
from CFS patients previously reported to contain XMRV
sequences were retested, however were identified as XMRV
negative by PCR amplification strategies and serology methods
[12,32].
Earlier this year, while this study was in progress, several
publications addressed the risk of contaminations by traces of
mouse DNA (paraffin sections, cell lines or other sources)
[7,13,15] and the risk of false positive PCR products by some
commercial amplification kits [17,33]. In addition, Hue and
colleagues argue that due to the lack of sequence variability of
XMRV gene fragments in patient isolates compared to sequence
variability identified in a XMRV positive cell line 22Rv1,
XMRV might be a laboratory contaminant rather than a true
exogenous human virus [11]. A strong indication that XMRV is
a virus circulating in the human population is the identification
of viral integration sites in the host genome [34]. However, more
recent findings demonstrate that two integration sites published
earlier are identical to XMRV integration sites in an in vitro
infected cell line DU145 [35]. Furthermore, Paprotka and
colleagues provide evidence that XMRV derived from two
mouse endogenous pre-viruses which underwent retroviral
recombination in cell culture thereby suggesting that all XMRV
sequences reported to date did most likely originate from this cell
culture event [14]. In the presented study we addressed the
detection of XMRV and related MLV sequences in peripheral
blood cells of prostate cancer patients and healthy controls
motivated by the detection of XMRV in blood cells of 3–4% of
healthy controls [2] and our hypothesis that XMRV replication
could be activated due to immunosuppression accompanying
PCA and subsequently detectable in the blood of patients. A
total of 100 blood samples were included in our study. PBMCs
were isolated, stimulated and subsequently used for genomic
DNA isolation or cocultivation experiments following published
protocols [1,2]. Furthermore, protein extracts from activated
PBMCs were generated and analysed for XMRV protein
expression. We show that PBMCs in general can be in vitro
infected with XMRV, resulting in 1–2% infected cells which can
be easily monitored by PCR or protein expression analyses
thereby confirming recently published results [10]. Although
viral genomes are highly edited due to Apobec restriction,
supernatant from XMRV infected PBMCs efficiently infects a
reporter cell line, DERSE-iGFP. This cell line (generated by
Vineet N. KewalRamani, National Cancer Institute, Frederick,
USA) expresses a GFP reporter which is activated by reverse
transcriptase expression. Although the sensitivity of all tech-
niques used in our study is fairly high, no XMRV sequences or
XMRV specific protein expression was detected in activated
PBMCs. Interestingly, we detected in supernatant from 3/67
activated PBMCs and 2/67 cocultivation experiments of PBMCs
with LNCaP cells, RT activity resulting in GFP positive DERSE-
iGFP cells, however, we were unable to unambiguously proof
that these PBMCs have been infected with XMRV, other
sources of RT activity can not be excluded.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee of the
Federal State Hamburg (no. OB-052-04).
Study population and specimen collection. Study
population and specimen collection
Blood samples of 92 prostate cancer patients (age 44–77) were
collected one day prior radical prostatectomy. Clinical data are
summarized in Table 1. Additionally, blood samples from 7 men
(age 30–44) without any evidence of PCA were included in the
study. All patients gave written informed consent for the scientific
use of blood samples; EDTA-blood from patients and healthy
controls were processed by density gradient centrifugation using
Ficoll (Biocoll, Biochrom L6715). Primary blood mononuclear
cells (PBMCs) were separated and cultivated as described below.
Cell lines
The human prostate cancer cell line LNCaP (ATCC #CRL-
1740), LNCaP DERSE-iGFP (kindly provided by Vineet N.
KewalRamani, National Cancer Institute, Frederick, USA) and
the XMRV positive human prostate cancer cell line 22Rv1
(ATCC #CRL-2505) were grown in RPMI 1640 (Gibco)
supplemented with 10% FCS, 5% Penicillin/Streptomycin and
L-glutamine. Chronically infected LNCaP cells (XMRV) were
generated by transfection of proviral XMRV VP62 DNA as
published previously [36] and maintained for several weeks.
PBMC were isolated from 10 ml EDTA blood and cultured in
RPMI 1640 (Gibco) similar to established prostate cancer cell lines
but additionally supplemented with PHA (5 mg/ml, Thermo
Fisher Scientific) and rhIL-2 (180 IU/ml, R&D Systems).
Table 1. Summary of clinical data.
Patients PBMCs n (%) 92
Age at surgery
mean (years) 63
median (years) 63
range (years) 44–77
Gleason
#3+3 7 (7.6)
3+46 9 ( 7 5 )
4+3 14 (15.2)
$4+4 2 (2.2)
T stage
pT2a 7 (7.6)
pT2c 57 (62)
pT3a 20 (21.7)
pT3b 8 (8.7)
N staus
N0 69 (75)
N1 4 (4.3)
Nx 19 (20.7)
doi:10.1371/journal.pone.0025592.t001
XMRV and Prostate Cancer
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1ml cell suspension containing 1610
6–3610
6 PBMCs activated
for 7 days was added to 2610
5 LNCaP cells maintained in 2ml
RPMI containing 8 mg/ml polybrene in 6-well plates. Plates were
centrifuged for 30 min at 37uC and 800 6 g. PBMCs were
removed 24h later. LNCaP cells were cultured for 6–8 weeks. Cells
were split when reaching 100% confluence. Supernatants were
taken after 6 and 8 weeks and applied to DERSE-iGFP cells (see
below).
For positive controls human PBMC were infected with XMRV-
containing supernatant from LNCaP XMRV cells. Indicated amount
of virus containing supernatant from XMRV producing cells (at least
80% confluence) was sterile filtered and added to 3610
6 PBMCs pre-
activated for two days. Plates were centrifuged for 30 min at 37uCa n d
800 6g. XMRV containing supernatant was removed the next day
by pelleting cells at 200 6g, washing them with 10 ml PBS (Gibco)
and disseminating after an additional centrifugation step in a new 6-
well plate in 2 ml RPMI containing PHA and rhIL-2. PBMCs were
cultivated for 7 days before analyzing supernatant, co-cultivation,
nucleic acid and protein extraction.
Infection using replication competent XMRV
XMRV VP62 proviral DNA was transfected into LNCaP cells to
produce virus containing supernatant as described earlier [34,36].
PCR
Genomic DNA was extracted from PBMCs using Qiagen QIAamp
mini kit and stored at 4uC. Nucleic acid concentrations were
determined using a Nanodrop (Peqlab). Different nested PCRs
targeting gag and env sequences were performed as recently published
[1,3,19], using 650 ng template DNA per reaction. Gag outside
primer: 419F 59- ATCAGTTAACCTACCCGAGTCGGAC-39,
1154R 59-GCCGCCTCTTCTTCATTGTTCTC-39;i n s i d ep r i m e r :
NP116F 59-CATGGGACAGACCGTAACTACC-39and NP117R
59-GCAGATCGGGACGGAGGTTG-39. To determine the sensi-
tivity of the Gag PCR originally published by Urisman et al. the
following primers were applied: GAG OF 59-CGCGTCTGATTT-
GTTTTGTT-39,G A GO R5 9- CCGCCTCTTCTTCATTGTTC-
39,G A GI F5 9- TCTCGAGATCATGGGACAGA-39 and GAG IR
59- AGAGGGTAAGGGCAGGGTAA [19]. The env PCR was
performed as recently published [3] using the following primer pairs F
59-ACCAGACTAAGAACTTAGAACCTCG-39,R 5 9-AGCTGTT-
CAGTGATCACGGGATTAG-39,I F5 9-GAACAGCATGGAAA-
GTCCAGCGTTC-39 and IR 59-CAGTGGATCGATACAGTCT-
TAGTCC-39. The integrity of the DNA samples and the presence of
putative inhibiters were controlled by amplifying GAPDH, F 59-
GAAGGTGAAGGTCGGAGTC-39 and R 59- GAAGATGG
TGATGGGATTTC-39.
Western Blot
Cell lysates were generated using RIPA buffer containing 1%
Triton-X 100 and protease inhibitor mix (Roche). Specific protein
bands were detected by polyclonal Env antibody Rauscher 77S85
(gift of C. Stocking, Heinrich-Pette Institute, Hamburg, Germany),
XMRV specific rabbit polyclonal Gag antiserum k121 and p30-
Gag recognizing hybridoma supernatant from CRL-1912 cells
(ATCC). Equal protein amounts per lane were ensured with anti-
human actin antibody mAB 1501 (Chemicon) incubation. For the
detection of XMRV particles in cell culture supernatants, sterile
filtered culture medium of infected cells was ultracentrifuged 1 h,
110.0006ga t4 uC (Beckman SW60Ti). The pellet of 11ml
supernatant was resuspended in 10 ml PBS and analyzed by
immunoblotting.
Cell line paraffin sections and TMAs
1610
7 cells (LNCaP, LNCaP chronically infected with XMRV,
293T, 293T chronically infected with XMRV and mouse SC1
cells) were fixed for 20 h in 10% phosphate buffered formalin,
embedded in agar and processed to paraffin wax [37].
A preexisting TMA containing prostate tissue (50 low grade
PCA, 50 high grade PCA and 50 benign prostate hyperplasia
(BPH)) was used for IHC.
Immunhistochemistry
Slides with paraffin sections of prostate cancer patients were
initially deparaffinized using xylene. For antigen retrieval sections
were heated 462 min in a citrate buffer using a microwave (650W)
and then cooled down to room temperature for 30 min. Blocking
wasperformed for 30 min at RTwith10% swine serum in antibody
dilution buffer (Dako). Afterwards endogenous biotin was blocked
using Avidin/Biotin Kit (Dako). Primary antibody (diluted in
antibody dilution buffer with 2% swine serum, anti-XMRV 1:7500;
XMRV anti-gag k121 1:5000) was incubated for 2 h at room
temperature in a humid chamber. Controls were either coated with
the corresponding pre serum (same dilution) or only with antibody
dilution buffer with 2% swine serum. The incubation with the
secondary antibody – biotin/streptavidin labeled – was performed
for 30 min at RT. For a later detection of bound antibodies labeled
sections were coated with alkaline phosphatase solution (Dako, AK
5000) accordingto manufactures instructions. IHCstaining solution
containing levamisole to inhibit endogenous alkaline phosphatase
was added to the slides for 15–20 min, while counterstaining was
performed with Mayers hamin solutions. The anti-XMRV serum
was kindly provided by Ila Singh (University of Utah, USA).
Results
XMRV protein expression in PCA tissue by IHC methods
In 2009, the finding of 23% of PCA sections positive for XMRV
protein expression has been reported [4]. XMRV protein expression
which in the majority of cases localized to the tumor epithelium
strongly correlated with higher Gleason grades. Interestingly, the
protein expression data did not correlate with PCR results. One
putative explanation being few focal infected XMRV cells in the
prostate which are hardly detectable by PCR using DNA from whole
mount tissue sections as template. However, these findings were not
confirmed by another study [24]. To contribute to the explanation of
the discrepancies we screened whole PCA sections as well as TMAs
using the recently published anti-XMRV serum [4] and a rabbit
polyclonal anti-XMRV gag serum (gag k121).
Both sera have been tested in Western Blot analyzes with gag
k121 serum specifically recognizing xenotropic gag protein while
displaying no cross reactivity with any cellular proteins. In contrast
the anti-XMRV serum [4] also recognized cellular proteins in non
infected human and mouse cell lines (supplementary Figure S1).
We generated paraffin sections representing human cell lines
293T, LNCaP, both cell lines infected with XMRV and a mouse
cell line SC1. Both antisera recognize XMRV protein expressing
cells in paraffin sections showing granular staining of the
cytoplasm (Figure 1). No staining of uninfected cells and no
staining of SC1 mouse cells was detected. A total of 100 PCA (low
grade and high grade PCA) and 50 BPH represented on a TMA as
well as 10 large sections of prostate cancer (with high Gleason
Score) were analyzed with gag k121 serum (Table 2). In addition a
TMA containing breast, colon and prostate cancer as well as
several normal tissues was tested for XMRV protein expression.
Each IHC staining was controlled by including positive controls
(paraffin sections of cell lines) and negative controls (without
XMRV and Prostate Cancer
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25592Figure 1. XMRV specific immunohistochemistry staining on cell line paraffin sections. Paraffin sections of cell line array containing XMRV
infected cell lines as well as non infected cell lines were stained for XMRV protein expression using anti-XMRV serum (A) or anti-gag k121 polyclonal
rabbit serum (B). Larger magnifications are displayed for XMRV infected cells as well as for a feral mouse cell line, SC1.
doi:10.1371/journal.pone.0025592.g001
Table 2. Summary of XMRV IHC on PCA sections and other common malignancies.
a-XMRV (Schlaberg et al., PNAS 2009) a-gag 121
PCA TMA n.t. 0/50 high grade PCA
0/50 low grade PCA
1/50 BPH
TMA* n.t. 0/114
PCA tissue sections 0/10 (high grade) 0/10 (high grade)
*: Neoplasia: Breast cancer, colon cancer; prostate cancer; Normal tissue: Adrenal gland, colon, endometrium, epididymis, heart, kidney, lung, pancreas, placenta,
parotid gland, prostate, skin, spleen, stomach, striated muscle, thymus, tonsil, testis.
doi:10.1371/journal.pone.0025592.t002
XMRV and Prostate Cancer
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antibody. No staining of cancer sections was observed as well as
the majority of control tissues was negative for gag k121 staining.
Only one section of BPH displayed very few random basal cells
staining positive with anti-gag k121 serum (Figure 2). None of the
TMA was tested with the anti-XMRV serum since high
background due to the TMA generation procedure has been
observed.
Activated PBMCs can be infected with XMRV, however
XMRV replication is restricted in PBMCs. Following the
hypothesis published by Lombardi et al, that XMRV can be
detected in PBMCs from up to 67% of CFS patients as well as in up
to 4% of healthy controls [2] we intended to activate PBMCs from
PCA patients and control patients and screen for XMRV infection
applying different methods. We first established our XMRV
detection methods on PBMCs which have been in vitro infected
with viral supernatant containing VP62 XMRV. Proviral DNA was
used to produce XMRV infectious supernatants in LNCaP cells
which strongly support XMRV replication due to strong activation
of the LTRas well as the lackof retroviralrestriction factorsApobec
3G expression [36,38–41]. PHA activated PBMCs were in vitro
infected with the indicated amounts of viral supernatant (Figure 3)
which were cultured in the presence of IL2 for another 7 d. Virus
containing supernatant was then subjected to ultracentrifugation
and viralpellets (Figure 3A) as well as cell lysate (Figure 3B)fromthe
infected PBMCs were analyzed by Western Blotting ensuring the
expression of XMRV specific proteins. Based on Western Blot
experiments using chronically infected LNCaP cells diluted with the
indicated cell number of uninfected 293T cells (Figure S2) we can
estimate that approximately 1–2% of PBMCs are infected with
XMRV.OnlyifweinfectPBMCswithhigh viraltitersweefficiently
detected XMRV in the viral pellet after ultracentrifugation and
Western Blot analysis (Figure 3A). Genomic DNA isolated from
these in vitro XMRV infected PBMCs was positive for XMRV
sequences by PCR using 650 ng genomic DNA and two different
primer sets targeting gag and env (Figure 4A and Figure S3).
Sensitivity of all PCR reactions is indicated in supplementary Figure
S4 with allPCRdetecting 1–10 infected cellsin a background of 10
6
uninfected cells.
Cocultivation of XMRV infected PBMCs with LNCaP
cells significantly increases sensitivity of XMRV
detection. DERSE-iGFP cells were exposed to filtered culture
supernatant from XMRV infected PBMCs. 500 ml of supernatant
was added to 5610
4 DERSE-iGFP cells which were scored for
GFP expression 7 d p.i. by microscopy and FACS analysis (Figure
3C). In general, viral supernatant from PBMCs is infectious,
however only very few GFP positive cells were detected.
Interestingly, if we cocultivate the XMRV infected PBMCs with
LNCaP cells for 5 d, harvest the supernatant and reinfect DERSE-
iGFP cells with filtered supernatant, sensitivity of XMRV
detection using DERSE-iGFP cells was 100fold increased Figure
3D and Figure 4B.
PBMCs of PCA patients are negative for XMRV detection
by PCR analysis
Using this approach we isolated PBMC from 92 PCA patients
and 7 healthy volunteers by Ficoll gradient; isolated PBMCs were
PHA activated and cultured in the presence of IL-2 for 7 d. PBMCs
were subjected to different assays as outlines in Figure 5A: genomic
DNA isolation followed by XMRV specific nested PCR applying
two published XMRV PCR strategies [1,3,19]; cocultivation of
activated PBMCs with LNCaP cells for 8 weeks with subsequent
infection of DERSE-iGFP cells using supernatant 6 weeks and 8
weeks after cocultivation. Localization of the different primer sets
used is shown in Figure S3 and sensitivity of the different XMRV
PCRs is reflected in Figure S4. The integrity of the genomic DNA
togetherwith theabsenceofputative PCRinhibitorswasensured by
GAPDH amplification (Figure S4). The culturing of PBMCs, DNA
preparations and the PCR amplification were performed in
laboratories of the Heinrich-Pette Institute where no other XMRV
studies were performed. In addition, all nested PCRs to detect
XMRV sequences using two different primer pairs targeting gag,
both recently published, as well as an env PCR were run by two
operators using 650 ng genomic DNA as template. All DNA
samples were found to be consistently negative (Table 3). PCR
reactions were routinely controlled for mouse contamination using
primers directed against retrotransposons, intracisternal A particle
(IAP), as recently published [15]. None of the PCR reactions was
positive for mouse DNA sequences (data not shown).
67 PBMC samples were cocultured with LNCaP cells for up to
8 weeks and SN of the LNCaP cells was applied to the reporter cell
line DERSE-iGFP. This cell line carries a MLV vector, which
leads to expression of a GFP reporter if reverse transcriptase is
expressed. 72 h p.i. DERSE-iGFP cells were monitored for GFP
expression by microscopy. Of 67 samples supernatant from
PBMCs cocultured with LNCaP cells, two resulted in 2–3 GFP
positive cells in 5610
4 cells (Figure 5B). We did not observe an
increase of GFP positive cells over time indicating that there was
no spread of viral infection. Interestingly the supernatant of the
Figure 2. Immunohistochemistry staining using anti-gag k121 polyclonal rabbit serum on TMAs representing prostate cancer
sections as well as benign prostate hyperplasia (BPH). In 1/50 BPH random positive stained cells were observed, which might be basal cells
based on their localization in the prostate.
doi:10.1371/journal.pone.0025592.g002
XMRV and Prostate Cancer
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also resulted in 1–2 GFP positive DERSE-iGFP cells per well. In
one case two independent PBMC isolations from the same patient
were performed (#99 and #100) which both resulted in 1–2 GFP
positive DERSE-iGFP cells. However, both isolations were
performed at the same day by the same operator. PCR from
LNCaP cells cocultured with PBMCs of these two patients did not
result in detection of XMRV specific sequences as well as we were
unable to culture and expand GFP positive DERSE-iGFP cells for
subsequent analyses.
Discussion
In this study we have examined the detection of XMRV in
prostate cancer patients by studying different diagnostic bio
specimens for the presence of XMRV or related MLV sequences.
In particular, we analyzed PCA tissue specimens as well as tissue
sections from other malignancies and normal tissues for XMRV
protein expression by IHC. Furthermore, PBMCs from 92 PCA
and 7 healthy controls were screened for the presence of XMRV
sequences and recovery of infectious virus. PBMCs were PHA
activated, cocultured for up to 8 weeks and XMRV presence was
examined by either nested PCR targeting two different XMRV
regions, Western Blot analyzes using different anti-XMRV
antibodies or infection of DERSE-iGFP cells applying supernatant
from activated PBMCs or supernatant from LNCaP cells
cocultured with PBMCs for up to 8 weeks.
We were unable to conclusively show that XMRV sequences
can be detected in activated PBMCs of PCA patients although in
two patients GFP positive DERSE-iGFP cells were detected. In
both cases subsequent PCR analyses of activated PBMCs as well as
cocultured LNCaP cells were negative for XMRV sequences as
well as we did not find XMRV protein expression in PCA sections
of one of these patients.
We previously published that XMRV sequences are only rarely
detected in Germany using cDNA generated from PCA tissue
RNA amplified by PCR [27]. Similar results for a study in the US
have been recently published by Switzer et al., [26]. However,
there are multiple studies not identifying any XMRV sequences in
PCA tissue as well as there are studies with higher prevalence of
XMRV in PCA [3,9,21–24,31,42]. Considering the possibility of
focal XMRV infection in the prostate which might be missed by
PCR amplification due to only a minority of cells infected we
established IHC staining using the published anti-XMRV serum
and an XMRV specific anti-gag serum. We failed to detect
XMRV protein expression in PCA tissue, breast cancer or colon
cancer tissue as well as most control tissue (including 10 sections
each: adrenal gland, colon, endometrium, epididymis, heart,
kidney, lung, pancreas, placenta, parotid gland, spleen, stomach,
striated muscle, thymus, tonsil, and testis) did not show any
positive staining for gag k121 serum. Interestingly, using the anti-
gag k121 serum we detected 1/50 BPH sections positive for
XMRV protein expression. Protein expression was identified in a
few isolated basal cells in the prostate epithelium. Basal cells are
absent in PCA, supporting the fact that XMRV most likely is not
directly involved in PCA development. The small number of
whole mount tissue sections examined could account for the
discrepancy between our findings and earlier findings by
Schlaberg et al. [4]. We only stained ten whole mount tissue
Figure 3. XMRV efficiently infects and replicates in peripheral
blood mononuclear cells (PBMCs). PBMCs from two different
donors were isolated, pooled, PHA stimulated and subsequently
infected with the indicated amounts of XMRV containing supernatant
(lane 1–5). Western Blot analysis of cell lysate from infected PBMCs was
performed 7 d past infection (B). Supernatant of the infected PBMCs
was enriched for virus particles by ultracentrifugation and stained for
CA expression (A). (C) 500 ml of XMRV containing supernatant
originated from PBMCs shown in A and B was used to infect DERSE-
iGFP cells which were analysed for GFP expression 7 d past infection by
FACS. Titers are indicated as GFP infectious units/ml. (D) Infection of
DERSE-iGFP cells is 100fold increased by cocultivation of infected
PBMCs (shown in (A)) with LNCaP cells for 7 d, SN of LNCaP cells was
then applied to DERSE-iGFP cells, which were analysed by FACS 5 d p.i..
doi:10.1371/journal.pone.0025592.g003
XMRV and Prostate Cancer
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used on TMA sections due to high background staining. Aloia et
al. and Sakuma et al. both discuss a cross reactivity of anti-XMRV
serum with human protein antigens resulting in IHC positive
staining in PCA sections [16,24]. We detect some cross reactivity
with the published anti-XMRV serum on Western Blots analyzing
cell lysates from infected and non infected cells, however there was
no background observed on paraffin sections of cell lines or on
Figure 4. Detection of XMRV infection in PBMCs in vitro infected with XMRV by PCR (A), 650 ng genomic DNA isolated from PBMCs
7 d past infection were used as template. (B) DERSE-iGFP cells were infected with 500 ml supernatant from 22Rv1 cells, mock infected cells or
LNCaP cells cocultured with XMRV infected PBMCs for 14 d. 72 h past infection DERSE-iGFP cells were monitored for GFP positive cells by microscopy.
doi:10.1371/journal.pone.0025592.g004
XMRV and Prostate Cancer
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25592Figure 5. Detection of XMRV in PBMCs isolated from PCA patients and healthy controls. (A) Methods used to screen for XMRV in PBMCs
of PCA patients and healthy controls. (B) DERSE-iGFP cells 72 h p.i. with SN from LNCaP cells cocultured for 8 weeks with patient derived PBMCs
(upper panels). The lower panels display DERSE-iGFP cells 72 h p.i. with SN from patient derived PBMCs which were activated with PHA for 7d.
doi:10.1371/journal.pone.0025592.g005
Table 3. Summary of XMRV detection in activated PBMCs from PCA patients using nested PCR amplification from genomic DNA
and coculture experiments on DERSE-iGFP cells.
Nested PCR Cell Culture
GAG (Urisman et al.
PLoS Pathog. 2006)
GAG (Lo et al.
PNAS 2010)
ENV (Danielson
et al. JID 2010)
PBMCs cocultured
with LNCaP
1
SN from PBMCs on
DERSE-iGFP cells
2
PCA Patients 0/93 0/93 0/93 2/67 3*/10
Healthy Controls 0/7 0/7 0/7 n.t. n.t.
1Activated PBMCs were cocultured with LNCaP cells for 8 weeks. Supernatant of these LNCaP cells was applied to DERSE-iGFP cells.
2Supernatant from activated PBMCs was applied to DERSE-iGFP cells without cocultivation with LNCaP cells.
*#99 and #100 derived from the same patient.
doi:10.1371/journal.pone.0025592.t003
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dilutions. Negative IHC staining does not exclude the possibility
of few cells carrying XMRV proviral sequences which we might
miss by PCR amplification. We did not apply DNA FISH
technology to detect XMRV proviral integration in human tissue.
Evaluation of FISH positive signal in 0.1% or less of the cells
especially if only one viral copy per cell is to be expected, is highly
error prone.
Recently, Lombardi et al. reported detection and transmission
of infectious XMRV from PBMCs or plasma of patients with CFS
by coculturing with LNCaP cells [2]. Interestingly, 3-4% of
PBMCs isolated from control patients were identified to be
positive for XMRV infectious virus resulting in the general
concern about the safety of blood products. Several subsequent
studies motivated by these results were unable to confirm these
original findings. Reasons for the discordance are unclear and are
currently investigated. While the majority of studies focussed on
PCR techniques as well as detection of XMRV specific antibodies
only one study included cocultivation of activated PBMCs from
CFS patients with LNCaP cells [10] and a more recent study
tested the transmission of XMRV from plasma (derived from CFS
patients) to LNCaP cells [43]. Both studies did not detect XMRV
in any of the samples tested. Focusing on the possibility that
XMRV is a bystander virus reactivated in prostate cancer patients
together with the finding that XMRV can be detected in PBMCs
of patients [2] we searched for signs of XMRV infection in blood
cells of PCA patients applying PCR technology and cocultivation
of activated PBMCs with indicator cells. To our knowledge the
current study is the first analyzing the presence of XMRV in blood
samples from PCA patients in general and from a larger number of
PBMCs (n=92) tested by labor intensive coculturing of activated
PBMCs with LNCaP cells for up to 8 weeks. A previous report by
Hohn et al. also used cocultivation of activated PBMCs with
subsequent genomic DNA isolation and XMRV specific amplifi-
cation. Here we cocultivated activated PBMCs with LNCaP cells
for up to 8 weeks (which increases sensitivity up to 100fold) and
tested supernatant of these LNCaP cells for XMRV release by
infection of DERSE-iGFP cells and subsequent FACS analysis or
microscopy study.
In two patients we identified isolated GFP positive DERSE-
iGFP cells when applying supernatant of activated PBMCs after
7 d as well as from the supernatant of LNCaP cells cocultivated for
8weeks with PBMCs. In all cases only very few positive cells were
detected which could not be subcultivated to achieve significant
cell numbers for subsequent experiments.
Taken together our data generated by analyzing different bio
specimen, in particular tissue sections and PBMCs, for signs of
XMRV infection do not support the association of XMRV with
prostate cancer. Since we did not apply FISH technology to detect
proviral integration we cannot exclude that few cell might show
XMRV integration. However, the question of XMRV existence is
different from the question of disease association. Our data are in
concordance with recently published results demonstrating that
XMRV can infect PBMCs in vitro [10,44]. We find that 1–2% of
PBMCs are infected when high amounts of viral titers are used for
in vitro infection. These PBMCs release XMRV, however less
viral particles are released compared to LNCaP cells and the virus
is highly edited. Nevertheless, XMRV released from PBMCs is
able to efficiently infect cells. Although we observed by two
different experiments that DERSE-iGFP cells after incubation
with supernatant from activated PBMCs express GFP in a few
cells, we were unable to conclusively show that XMRV can be
reactivated from PBMCs and infect an indicator cells line: no PCR
detection of XMRV was achieved as well as the ultimate proof,
cloning of integration sites from patients, is impossible from this
material. At no time did we observe spontaneous GFP expression
of DERSE-iGFP cells or GFP expression due to exogenous
contamination of our cell culture, still contamination can not be
experimentally ruled out.
In summary, we applied multiple methods to detect XMRV in
bio specimen of prostate cancer patients; the results of our study do
not support an association of XMRV and prostate cancer.
Supporting Information
Figure S1 Western Blot analysis of XMRV negative (293T;
LNCaP), XMRV positive human cell lines (22Rv1), chronically
infected human cell lines (293T-XMRV; LNCaP-XMRV) as well
as mouse cell lines (inbred NIH3T3 and feral mouse cells SC1)
using rabbit polyclonal a-gag k121 serum (A) or rabbit polyclonal
a-XMRV serum [4] (B) for detection.
(TIF)
Figure S2 Western Blot analysis of diluting amounts of
chronically XMRV infected LNCaP cells mixed with non infected
293T cells. 25 mg total protein lysate was loaded per lane. Blots
were immunoblotted using goat-anti env serum and rabbit-anti
gag k121 serum. To ensure equal protein amounts loaded per lane
the blot was reprobed with anti-actin monoclonal antibody.
(TIF)
Figure S3 XMRV VP62 Gag sequence 407-1160
(GI:89889045). Primers are indicated as arrows, GAG-O/I dark
grey, 419F/1154R and NP116/NP117 light grey. Sequence
variability between XMRV and MLV related sequences located
in the indicated primer sequences are labeled with a star (*).
(TIF)
Figure S4 Genomic DNA was isolated from 1610
6 cells
(indicated number of chronically XMRV infected LNCaP cells
mixed with non infected 293T cells in 10 fold dilutions of infected
cells in non infected cells). Nested PCR was performed using the
oligos GAG-O and GAG-I [19], 419F/1154R and NP116/NP117
[1] as well as env primers 5604F/6491R and 5742F/6394R [3].
The highest dilution still showing XMRV specific amplification
products in labelled with an *.
(TIF)
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